High-Dose Chemotherapy With Autologous Hematopoietic Stem Cell Support for Solid Tumors in Adults

Seminars in Hematology

Volumn 44, Issue 4, 2007, Pages 286-295

  Pedrazzoli, Paolo ^a   Rosti, Giovanni ^b   Secondino, Simona ^a   Carminati, Ornella ^c   Demirer, Taner ^d  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

^b OSPEDALE CA FONCELLO   (Italy)

^c Department of Oncology ^*  (Italy)

^d ANKARA UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BLEOMYCIN; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; HORMONE RECEPTOR; IFOSFAMIDE; MELPHALAN; METHOTREXATE; MITOXANTRONE; PACLITAXEL; TAXANE DERIVATIVE; THIOTEPA;

ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE METASTASIS; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMOSENSITIVITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DOSAGE SCHEDULE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG MEGADOSE; FOLLOW UP; GERM CELL TUMOR; HUMAN; INTERMETHOD COMPARISON; LEUKEMIA; LUNG SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; OVARY CARCINOMA; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SALVAGE THERAPY; SOLID TUMOR; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR LOCALIZATION; UNSPECIFIED SIDE EFFECT;

ADULT; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARBOPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; EVIDENCE-BASED MEDICINE; FEMALE; GERMINOMA; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; NEOPLASMS; OVARIAN NEOPLASMS; SALVAGE THERAPY; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 35348958398     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2007.08.009     Document Type: Article

References (68)

1. Skipper H.E. Dose intensity versus total dose of chemotherapy: An experimental basis. In: De Vita V.T., Hellman S., and Rosenberg S.A. (Eds). Important Advances in Oncology (1990), Lippincott, Philadelphia, PA 43-64
2. Pedrazzoli P., Ferrante P., Kulekci A., Schiavo R., De Giorgi U., Carminati O., et al. Autologous hematopoietic stem cell transplantation for breast cancer in Europe: Critical evaluation of data from the European Group for Blood and Marrow Transplantation (EBMT) Registry 1990-1999. Bone Marrow Transplant 32 (2003) 489-494
3. Eder J., Antman K., Peters W., Henner W.D., Elias A., Shea T., et al. High-dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancer. J Clin Oncol 4 (1986) 1592-1597
4. Peters W.P., Ross M., Vredenburgh J.J., Meisenberg B., Marks L.B., Winer E., et al. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 11 (1993) 1132-1143
5. Gianni A.M., Siena S., Bregni M., Di Nicola M., Orefice S., Cusumano F., et al. Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: Five-year results. J Clin Oncol 15 (1997) 2312-2321
6. Siena S., Schiavo R., Pedrazzoli P., and Carlo-Stella C. Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy. J Clin Oncol 18 (2000) 1360-1377
7. Weiss R.B., Rifkin R.M., Stewart F.M., Theriault R.L., Williams L.A., Hermann A.A., et al. High-dose chemotherapy for high-risk primary breast cancer: An on-site review of the Bezwoda study. Lancet 355 (2000) 999-1003
8. Gratwohl A., Schmid O., Baldomero H., Horisberger B., and Urbano-Ispizua A. Haematopoietic stem cell transplantation (HSCT) in Europe 2002. Changes in indication and impact of team density. A report of the EBMT activity survey. Bone Marrow Transplant 34 (2004) 855-875
9. Hanrahan E.O., Broglio K., Frye D., Buzdar A.U., Theriault R.L., Valero V., et al. Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma: Follow-up at 12 years. Cancer 106 (2006) 2327-2336
10. Schrama J.G., Faneyte I.F., Schronagel J.H., Baars J.W., Pertese J.L., van de Vijver M.J., et al. Randomized trial of high-dose chemotherapy and hematopoietic progenitor-cell support in operable breast cancer with extensive lymph node involvement: Final analysis with 7 years of follow-up. Ann Oncol 13 (2002) 689-698
11. Tokuda Y., Tajima T., Narabayashi M., Takeyama T., Watanabe T., Fukutomi T., et al. Randomized phase 3 study of high-dose chemotherapy (HDC) with autologous stem cell support as consolidation in high-risk postoperative breast cancer: Japan Clinical Oncology (JCOG9208). Proc Am Soc Clin Oncol 20 (2001) 38a (abstr)
12. Bergh J., Wiklund T., Erikstein B., Lidbrink E., Lindman H., Malmström P., et al. Tailored fluorouracil, epirubicin and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: A randomized trial. Scandinavian Breast Group 9401 study. Lancet 356 (2000) 1384-1391
13. Leonard R.C., Lind M., Twelves C., Coleman R., van Belle S., Wilson C., et al. Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: A randomized trial. J Natl Cancer Inst 96 (2004) 1076-1083
14. Zander A.R., Kroger N., Schmoor C., Kruger W., Möbus V., Frickhofen N., et al. High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: First results of a randomized trial. J Clin Oncol 22 (2004) 2273-2283
15. Coombes R.C., Howell A., Emson M., Peckitt C., Gallagher C., Bengala, et al. High dose chemotherapy and autologous stem cell transplantation as adjuvant therapy for primary breast cancer patients with four or more lymph nodes involved: Long-term results of an international randomised trial. Ann Oncol 16 (2005) 726-734
16. Tallman M.S., Gray R., Robert N.J., LeMaistre C.F., Osborne C.K., Vaughan W.P., et al. Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem cell transplantation in high risk breast cancer. N Engl J Med 349 (2003) 17-26
17. Elfenbein G.J. Stem-cell transplantation for high-risk breast cancer. N Engl J Med 349 (2003) 80-82
18. Peters W.P., Rosner G.L., Vredenburgh J.J., Shpall E.J., Crump M., Richardson P.G., et al. Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: A report of CALGB 9082, SWOG 9114, and NCIC MA-13. J Clin Oncol 23 (2005) 2191-2200
19. Peters W.P., Rosner G., Vredenburgh J., Shpall E., Crump M., Richardson P., et al. A prospective, randomized comparison of two doses of combination alkylating agents (AA) as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes (LN): Preliminary results of CALGB 9082/SWOG 9114/NCIC MA-13. Proc Am Soc Clin Oncol 18 (1999) 1a (abstr)
20. Roché H., Pouillard P., Meyer N., Biron P., Spielmann M., Janvier M., et al. Adjuvant high-dose improves early outcome for high-risk (N>7) breast cancer patients: The PEGASE-01 trial. Proc Am Soc Clin Oncol 20 (2001) 26a (abstr)
21. Gianni A., and Bonadonna G. Five-year results of the randomized clinical trial comparing standard versus high-dose myeloablative chemotherapy in the adjuvant treatment of breast cancer with >3 positive nodes (LN+). Proc Am Soc Clin Oncol 20 (2001) 21a (abstr)
22. Basser R.L., O'Neill A., Martinelli G., Green M.D., Peccatori F., Cinieri S., et al. Multicycle dose-intensive chemotherapy for women with high-risk primary breast cancer: Results of International Breast Cancer Study Group Trial 15-95. J Clin Oncol 24 (2006) 370-378
23. Rodenhuis S., Bontenbal M., van Hoesel Q.G., Smit W.M., Nooij M.A., Voest E.E., et al. Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer. Ann Oncol 17 (2006) 588-596
24. Nitz U.A., Mohrmann S., Fisher J., Lindemann W., Berdel W.E., Jackisch C., et al. Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: Results of a multicentre phase III trial. Lancet 366 (2005) 1935-1944
25. Martin M., Pienkowski T., Mackey J., Pawlicki M., Guastalla J.P., Weaver C., et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 352 (2005) 2302-2313
26. De Giorgi U., Rosti G., Frassineti L., Kopf B., Giovannini N., Zumaglini F., et al. High-dose chemotherapy for triple negative breast cancer. Ann Oncol 18 (2007) 202-203
27. Diallo-Danebrock R., Ting E., Gluz O., Herr A., Mohrmann S., Geddert H., et al. Protein expression profiling in high-risk breast cancer patients treated with high-dose or conventional dose-dense chemotherapy. Clin Cancer Res 13 (2007) 488-497
28. Crump M., Glück S., Stewart D., Levine M., Pritchard K., Kirkbride P., et al. A randomized trial of high-dose chemotherapy (HDC) with autologous peripheral blood stem cell support (ASCT) compared to standard therapy in women with metastatic breast cancer: A National Cancer Institute of Canada (NCIC) clinical trials group study. (abstract). Proc Am Soc Clin Oncol 20 (2001) 21a (abstr)
29. Stadtmauer E.A., O'Neill A., Goldstein L.J., Crilley P.A., Mangan K.F., Ingle J.N., et al. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group. N Engl J Med 342 (2000) 1069-1076
30. Stadtmauer E.A., O'Neill A., Goldstein L.J., Crilley P.A., Mangan K.F., Ingle J.N., et al. Conventional-dose chemotherapy compared with high-dose chemotherapy (HDC) plus autologous stem cell transplantation (SCT) for metastatic breast cancer: 5-year update of the 'Philadelphia Trial' (PBT-1). Proc Am Soc Clin Oncol 69 (2002) 43a (abstr)
31. Biron P., Durand M., Rochè H., Delozier T., Battista C., Fargeot P., et al. High dose thiotepa, cyclophosphamide and stem cell transplantation after 4 FEC 100 compared with 4 FEC alone allowed a better disease free survival but the same overall survival in first line chemotherapy for metastatic breast cancer. Results of the PEGASE 03 French Protocol. Proc Am Soc Clin Oncol 21 (2002) 42a (abstr)
32. Lotz J.P., Cure H., Janvier M., Asselain B., Morvan F., Legros M., et al. High-dose chemotherapy with haematopoietic stem cell transplantation for metastatic breast cancer patients: Final results of the French multicentric randomised CMA/PEGASE 04 protocol. Eur J Cancer 41 (2005) 71-80
33. Vredenburgh J.J., Madan B., Coniglio D., Ross M., Broadwater G., Niedzwiecki D., et al. A randomized phase III comparative trial of immediate consolidation with high-dose chemotherapy and autologous peripheral blood progenitor cell support compared to observation with delayed consolidation in women with metastatic breast cancer and only bone metastases following intensive induction chemotherapy. Bone Marrow Transplant 37 (2006) 1009-1015
34. Vredenburgh J.J., Coniglio D., Broadwater G., Jones R.B., Ross M., Shpall E.J., et al. Consolidation with high-dose combination alkylating agents with bone marrow transplantation significantly improves disease-free survival in hormone-insensitive metastatic breast cancer in complete remission compared with intensive standard-dose chemotherapy alone. Biol Blood Marrow Transplant 12 (2006) 195-203
35. Schmid P., Schippinger W., Nitsch T., Huebner G., Heilmann V., Schultze W., et al. Up-front tandem high-dose chemotherapy compared with standard chemotherapy with doxorubicin and paclitaxel in metastatic breast cancer: results of a randomized trial. J Clin Oncol 23 (2005) 432-440
36. Crown J., Perey L., Lind M., Guillem V., Efremdis A., Garcia-Conde J., et al. Superiority of tandem high-dose chemotherapy (HDC) versus optimized conventionally-dosed chemotherapy (CDC) in patients (patients) with metastatic breast cancer (MBC): The International Randomized Breast Cancer Dose Intensity Study (IBDIS). Proc Am Soc Clin Oncol 22 (2003) 23 (abstr)
37. Nieto Y., Nawaz S., Jones R.B., Shpall E.J., Cagnoni P.J., Mcweeney P.A., et al. Prognostic model for relapse after high-dose chemotherapy with autologous stem-cell transplantation for stage IV oligometastatic breast cancer. J Clin Oncol 20 (2002) 707-718
38. Kurian S., Qazilbash M., Fay J., Wolff S., Herzig R., Hobbs G., et al. Complete response after high-dose chemotherapy and autologous hemopoietic stem cell transplantation in metastatic breast cancer results in survival benefit. Breast J 12 (2006) 531-235
39. Kroger N., Frick M., Gluz O., Mohrmann S., Metzner B., Jackisch C., et al. Randomized trial of single compared with tandem high-dose chemotherapy followed by autologous stem-cell transplantation in patients with chemotherapy-sensitive metastatic breast cancer. J Clin Oncol 24 (2006) 3919-3926
40. Pedrazzoli P., Ledermann J.A., Lotz J.P., Leyvraz S., Aglietta M., Rosti G., et al. High dose chemotherapy with autologous hematopoietic stem cell support for solid tumors other than breast cancer in adults. Ann Oncol 17 (2006) 1479-1488
41. Elias A. Hematopoietic stem cell transplantation for small cell lung cancer. Chest 116 suppl 6 (1999) 531S-538S
42. Humblet Y., Symann M., Bosly A., Delaunois L., Francis C., Machiles J., et al. Late intensification chemotherapy with autologous bone marrow transplantation in selected small-cell carcinoma of the lung; a randomized study. J Clin Oncol 5 (1987) 1864-1873
43. Woll P.J., Thatcher N., Lomax L., Hodgetts J., Ming Lee S., et al. Use of hematopoietic progenitors in whole blood to support dose-dense chemotherapy: A randomized phase II trial in small-cell lung cancer patients. J Clin Oncol 19 (2001) 712-719
44. Lorigan P., Woll P.J., O'Brien M.E., Ashcroft L.F., Sampson M.R., and Thatcher N. Randomized phase III trial of dose-dense chemotherapy supported by whole blood hematopoietic progenitors in better-prognosis small-cell lung cancer. J Natl Cancer Inst 97 (2005) 666-674
45. Leyvraz S., Pampallona S., Martinelli G., Ploner F., Aversa S., Brunsvig P., et al. High-dose sequential chemotherapy supported by peripheral blood progenitor cells for the treatment of small cell lung cancer (SCLC): Results of the EBMT Random-ICE trial. Proc EBMT Bone Marrow Transplant 39 (2007) O172 (abstr)
46. Rosti G., Carminati O., Monti M., Tamberi S., and Marangolo M. Chemotherapy advances in small cell lung cancer. Ann Oncol 17 suppl 5 (2006) v99-v102
47. Kondagunta G.V., Bacik J., Sheinfeld J., Bajorin D., Bains M., Reich L., et al. Paclitaxel plus ifosfamide followed by high-dose carboplatin plus etoposide in previously treated germ cell tumors. J Clin Oncol 25 (2007) 85-90
48. Einhorn L.H., Williams S.D., Chamness B.A., Brames M.J., Perkins S.M., and Abanour R. High-dose chemotherapy and stem cell rescue for metastatic germ-cell tumors. N Engl J Med 357 (2007) 340-348
49. Lotz J.-P., Bui P., Gomez, Théodore C., Fizazi K., et al. Refractory germ cell tumors (GCTs): Salvage high-dose chemotherapy(HD-CT) combining 2 mobilization regimes followed by 3 GD-CT with peripheral blood stem cell transplantation PBSCT: The TAXIF regimen (GETUG). Ann Oncol 16 (2005) 411-418
50. Beyer J., Kramar A., Mandanas R., Linkesch W., Greinix A., Droz J.P., et al. High-dose chemotherapy as salvage treatment in germ cell tumors: A multivariate analysis of prognostic variables. J Clin Oncol 14 (1996) 2638-2645
51. Rosti G., De Giorgi U., Salvioni R., Papiani G., Sebastiani M., Argnani M., et al. Salvage high-dose chemotherapy in patients with germ cell tumors: An Italian experience with 84 patients. Cancer 95 (2002) 309-315
52. Bhatia S., Abanour R., Porcu P., Shesadri R., Nichols C.R., Cornetta K., et al. High dose chemotherapy as initial salvage chemotherapy in patients with relapsed testicular cancer. J Clin Oncol 18 (2000) 3346-3351
53. Pico J.L., Rosti G., Kramar A., Wandt H., Koza V., Salvioni R., et al. A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumors. Ann Oncol 16 (2005) 1152-1159
54. Schmoll H.J., Kollmannsberger C., Metzner B., Hartmann J.T., Schleucher N., Schoffski P., et al. Long-term results of the first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group. J Clin Oncol 21 (2003) 4083-4091
55. Rosti G., De Giorgi U., Wandt H., Liure B., Leyvraz S., Kolbe K., et al. First-line high-dose chemotherapy for patients with poor prognosis extragonadal germ cell tumors: The experience of the European Group for Blood and Marrow Transplantation (EBMT) Solid Tumors Working Party. Bone Marrow Transplant 34 (2004) 1033-1037
56. Bokemeyer C., Schleucher N., Metzner B., Thomas M., Rick O., Schmoll H.J., et al. First-line sequential high-dose VIP chemotherapy with autologous transplantation for patients with primary mediastinal nonseminomatous germ cell tumours: A prospective trial. Br J Cancer 89 (2003) 29-35
57. Motzer R.J., Nichols C.J., Margolin K.A., Bacik J., Richardson P.G., Vogelzang N.J., et al. Phase III randomised trial of conventional-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. J Clin Oncol 25 (2007) 247-256
58. Van Dijk M.R., Steyerberg E.W., and Habbema D.F. Survival of non-seminomatous germ cell cancer patients according to the IGCC classification: An update based on meta-analysis. Eur J Cancer 42 (2006) 820-826
59. Stiff P.J., Bayer R., Kerger C., Potkul R.K., Malhotra D., Peace D.J., et al. High-dose chemotherapy with autologous transplantation for persistent/relapsed ovarian cancer: A multivariate analysis of survival for 100 consecutively treated patients. J Clin Oncol 15 (1997) 1309-1317
60. Legros M., Dauplat J., Fleury J., Cure H., Suzanne F., Chassagne J., et al. High-dose chemotherapy with hematopoietic rescue in patients with stage III to IV ovarian cancer: Long term results. J Clin Oncol 15 (1997) 1302-1308
61. Lederman J.A., Herd R., Maraninchi D., Viens P., Buclon M., Philip T., et al. High-dose chemotherapy for ovarian carcinoma: Long term results from the Solid Tumour Registry of the European Group for Blood and Marrow Transplantation (EBMT). Ann Oncol 12 (2001) 639-699
62. Stiff P., Veum-Stone J., Lazarus H.M., Ayash L., Edwards J.R., Keating A., et al. High-dose chemotherapy and autologous stem-cell transplantation for ovarian cancer: An autologous blood and marrow transplant registry. Ann Intern Med 133 (2000) 504-515
63. Cure H., Battista C., Guastalla J.P., Fabbro M., Tubiana N., Bourgeois H., et al. Phase III randomised trial of high-dose chemotherapy (HDC) and peripheral blood stem cells (PBSC) support as consolidation in patients (patients) with responsive low-burden advanced ovarian cancer (AOC): A 5-year follow-up of a GINECO/FNCLCC/SFGM-TC study. Proc Am Soc Clin Oncol 22 (2004) 5006 (abstr)
64. Ledrman J.A., Frickhofen N., Wandt, Bengala C., Champion K., Hinke V., et al. A phase III randomised trial of sequential high dose chemotherapy (HDC) for first-line treatment of ovarian cancer. Proc Am Soc Clin Oncol 23 (2005) 5006 (abstr)
65. Hortobagyi G.N. What is the role of high-dose chemotherapy in the era of targeted therapies?. J Clin Oncol 22 (2004) 2263-2266
66. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., Goldhirsch A., Untch M., Smith I., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353 (2005) 1659-1672
67. Geyer C.E., Forster J., Lindquist D., Chan S., Romieu C.G., Pienkowski T., et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355 (2006) 2733-2743
68. Siena S. Towards the integration of hematopoietic stem cells into therapy of breast cancer?. Haematologica 84 (1999) 865-867